Pillstats
Rx only · Tablet, Film Coated, Extended Release · Oral

Dalfampridine

Brands: Ampyra · Dalfampridine

8 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US9 NDCs
8 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)897018
US makers8 labelers
Packages13
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.129$0.258$0.387$0.516Dec 2025Apr 2026Jul 2026
$0.413
Latest avg · Jul 22, 2026
-8%
Since Dec 17, 2025
8
Active US suppliers
46%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

1.6K3.2K4.9K6.5K2025 Q12025 Q22025 Q32025 Q42026 Q1
4.4K
Rx · 2026 Q1
293K
Units dispensed
-17%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it8 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Aurobindo Pharma Limitedunknown3SUPPLYING
Ascend Laboratories, LLCunknown3SUPPLYING
Merz Pharmaceuticals, LLCunknown2SUPPLYING
Bryant Ranch Prepackrepackager1SUPPLYING
Accord Healthcare Inc.unknown1SUPPLYING
Golden State Medical Supply, Inc.unknown1SUPPLYING
Actavis Pharma, Inc.unknown1SUPPLYING
CivicaScript LLCunknown1SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.